AU
UK
CA
NZ
IND
US
Last update at 2026-06-23T15:03:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
C.H. Robinson (CHRW) Surges 5.7%: Is This an Indication of Further Gains?
Thu 10 Apr 25, 02:39 PMUBS Says It’s Time to Go Bargain Hunting; Here Are 2 Stocks Poised for a Rebound
Fri 04 Apr 25, 10:03 AM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -32.17000M | -99.34800M | -35.09400M | -35.09400M | -273.84200M |
| Minority interest | - | - | - | - | - |
| Net income | 70.30M | -99.58700M | -37.33300M | -37.33300M | -275.52800M |
| Selling general administrative | 102.82M | 148.98M | 140.70M | 120.06M | 97.56M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 83.05M | 99.33M | 103.87M | 103.87M | 96.58M |
| Reconciled depreciation | 27.71M | 30.76M | 26.17M | 22.77M | 20.25M |
| Ebit | -36.80600M | -93.84500M | -28.95200M | -31.90400M | -17.82900M |
| Ebitda | -11.65300M | -66.35800M | -6.18700M | -37.42600M | -20.65200M |
| Depreciation and amortization | 25.15M | 27.49M | 22.77M | -5.52200M | -2.82300M |
| Non operating income net other | - | - | - | - | -251.32400M |
| Operating income | -36.80600M | -115.15700M | -31.90400M | -31.90400M | -17.82900M |
| Other operating expenses | 212.98M | 348.41M | 269.18M | 269.18M | 240.44M |
| Interest expense | 2.36M | 5.50M | 6.14M | 6.14M | 4.69M |
| Tax provision | 1.80M | 1.28M | 3.08M | 2.24M | 1.69M |
| Interest income | - | - | - | - | - |
| Net interest income | -2.36100M | -4.10800M | -5.65300M | -6.14200M | -4.68900M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.80M | 0.24M | 2.24M | 2.24M | 1.69M |
| Total revenue | 176.18M | 233.25M | 237.28M | 237.28M | 222.61M |
| Total operating expenses | 119.86M | 214.49M | 135.78M | 135.78M | 114.41M |
| Cost of revenue | 93.12M | 133.92M | 133.40M | 133.40M | 126.03M |
| Total other income expense net | 4.64M | 15.81M | -3.19000M | -3.19000M | -256.01300M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -33.96900M | -114.75600M | -46.63400M | -37.33300M | -275.52800M |
| Net income applicable to common shares | - | - | - | -45.33300M | -283.72400M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 764.99M | 703.49M | 957.74M | 1038.75M | 1112.97M |
| Intangible assets | 138.08M | 170.46M | 194.38M | 191.01M | 201.43M |
| Earning assets | - | - | - | - | - |
| Other current assets | 8.42M | 11.57M | 10.08M | 9.32M | 8.80M |
| Total liab | 262.35M | 301.59M | 468.72M | 482.91M | 471.14M |
| Total stockholder equity | 502.64M | 401.90M | 489.02M | 555.84M | 641.83M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 12.98M | 16.94M | 12.44M | 8.46M | 9.91M |
| Common stock | 0.05M | 0.05M | 0.05M | 0.05M | 0.05M |
| Capital stock | 42.33M | 34.33M | 26.32M | 18.32M | 10.32M |
| Retained earnings | -688.88400M | -757.17500M | -642.41900M | -542.83200M | -467.54100M |
| Other liab | - | - | - | 10.06M | 5.04M |
| Good will | 22.40M | 51.66M | 108.40M | 151.12M | 146.95M |
| Other assets | - | - | 0.00000M | 1.96M | 1.37M |
| Cash | 250.49M | 45.29M | 46.35M | 36.59M | 139.10M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 219.02M | 64.56M | 45.61M | 40.85M | 42.65M |
| Current deferred revenue | 0.94M | 1.11M | 1.31M | 0.44M | 0.55M |
| Net debt | -19.77600M | 205.41M | 369.66M | 399.31M | 287.95M |
| Short term debt | 189.81M | 20.35M | 5.81M | 3.91M | 3.60M |
| Short long term debt | 185.26M | 14.44M | 0.15M | 0.13M | - |
| Short long term debt total | 230.72M | 250.70M | 416.00M | 435.91M | 427.06M |
| Other stockholder equity | 1152.68M | 1145.68M | 1131.18M | 1114.90M | 1100.29M |
| Property plant equipment | - | - | - | 90.48M | 69.70M |
| Total current assets | 476.17M | 341.57M | 535.11M | 604.18M | 693.52M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 195.44M | 293.45M |
| Short term investments | 160.71M | 216.46M | 410.41M | 486.73M | 489.70M |
| Net receivables | 33.36M | 45.78M | 42.07M | 43.86M | 39.41M |
| Long term debt | 1.09M | 185.03M | 379.89M | 407.06M | 405.26M |
| Inventory | 23.19M | 22.47M | 26.21M | 27.68M | 16.50M |
| Accounts payable | 15.28M | 26.17M | 26.05M | 28.05M | 28.58M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -3.48300M | -20.92900M | -26.06500M | -34.54900M | -1.24300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 0.05M |
| Preferred stock total equity | - | - | - | - | 10.28M |
| Retained earnings total equity | - | - | - | - | -467.54100M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.09M | 2.90M | 1.68M | 1.02M | 1.37M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 288.81M | 361.92M | 422.63M | 434.57M | 419.45M |
| Capital lease obligations | 44.37M | 51.23M | 35.97M | 28.72M | 21.80M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 59.59M | 176.81M | 57.93M | -59.68100M | -438.70700M |
| Change to liabilities | - | - | - | -7.42400M | -0.06500M |
| Total cashflows from investing activities | 250.32M | 176.81M | 36.05M | -59.68100M | -469.25400M |
| Net borrowings | -15.03500M | -164.32100M | -25.27600M | -3.26200M | 36.61M |
| Total cash from financing activities | -21.07400M | -161.53100M | -23.79800M | -39.17400M | 564.34M |
| Change to operating activities | - | - | - | -2.65800M | 6.35M |
| Net income | 70.30M | -114.75600M | -99.58700M | -37.33300M | -275.52800M |
| Change in cash | 205.21M | -1.05700M | 9.75M | -102.50600M | 102.23M |
| Begin period cash flow | 45.29M | 46.35M | 36.59M | 139.10M | 36.87M |
| End period cash flow | 250.49M | 45.29M | 46.35M | 36.59M | 139.10M |
| Total cash from operating activities | -8.58000M | -16.32300M | -0.75700M | -1.85100M | 8.13M |
| Issuance of capital stock | - | - | 0.00000M | 0.00000M | 518.74M |
| Depreciation | 27.71M | 30.76M | 27.49M | 22.77M | 20.25M |
| Other cashflows from investing activities | 206.47M | -4.32600M | -5.13900M | 3.00M | -6.66500M |
| Dividends paid | 8.00M | 8.00M | 8.00M | -8.00000M | -8.19600M |
| Change to inventory | -2.18500M | 3.25M | 1.51M | -14.20400M | -5.97900M |
| Change to account receivables | -6.52700M | -4.14900M | 3.67M | -4.13700M | -7.27000M |
| Sale purchase of stock | -10.01100M | 0.00000M | 23.60M | -37.96000M | 8.20M |
| Other cashflows from financing activities | 8.00M | 8.00M | 1.48M | 8.00M | 297.97M |
| Change to netincome | - | - | - | 38.56M | 269.13M |
| Capital expenditures | 16.44M | 17.25M | 44.90M | 24.20M | 25.01M |
| Change receivables | - | - | - | - | -7.27000M |
| Cash flows other operating | - | - | - | - | 4.24M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | 103.21M |
| Change in working capital | -14.35500M | -8.60900M | 0.78M | -28.42300M | -6.96300M |
| Stock based compensation | 11.03M | 19.70M | 22.81M | 20.08M | 15.35M |
| Other non cash items | -103.93100M | 56.58M | 49.73M | 20.11M | 1.24M |
| Free cash flow | -25.01900M | -33.57700M | -45.65700M | -26.04800M | -16.88100M |
Sector: Industrials Industry: Integrated Freight & Logistics
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CYRX Cryoport Inc |
-0.08 0.54% | 14.69 | - | 70.42 | 3.04 | 1.15 | 2.21 | -13.0008 |
| UPS United Parcel Service Inc |
-0.74 0.69% | 106.50 | 16.03 | 15.92 | 1.44 | 6.98 | 1.63 | 10.04 |
| FDX FedEx Corporation |
-6.09 1.85% | 322.69 | 21.06 | 17.86 | 1.02 | 3.16 | 1.39 | 11.61 |
| DHLGY Deutsche Post AG |
-0.14 0.48% | 29.21 | 16.10 | 15.72 | 0.78 | 2.52 | 0.95 | 7.03 |
| DSDVY DSV Panalpina A/S ADR |
-0.69 0.59% | 116.51 | 48.35 | 24.63 | 0.26 | 3.46 | 1.99 | 20.03 |
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
112 Westwood Place, Brentwood, TN, United States, 37027
| Name | Title | Year Born |
|---|---|---|
| Mr. Jerrell W. Shelton | Chairman, Pres & CEO | 1945 |
| Mr. Robert S. Stefanovich | Sr. VP, CFO, Treasurer & Corp. Sec. | 1965 |
| Dr. Mark W. Sawicki Ph.D. | Sr. VP & Chief Scientific Officer | NA |
| Tony Ippolito | VP & Gen. Counsel | NA |
| Mr. Thomas J. Heinzen | VP of Corp. Devel. | NA |
| Mr. Bret Bollinger | Chief Technology Officer of Cryoport Systems, LLC | 1967 |
| Mr. Phil Wilson | Chief Operating Officer of Cryoport Systems, LLC | NA |
| Mr. Raymond Takahashi M.D. | Exec. Officer | NA |
| Mr. David Petreccia M.D. | Exec. Officer | NA |
| Mr. Bret Bollinger | VP & Chief Innovation Officer | 1967 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...